EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 (ots/PRNewswire) -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than ...
plus